CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Koelzer, Viktor H ^a   Lugli, Alessandro ^a   Dawson, Heather ^a   Hädrich, Marion ^b   Berger, Martin D ^b   Borner, Markus ^d   Mallaev, Makhmudbek ^a,b   Galván, José A ^a   Amsler, Jennifer ^a   Schnüriger, Beat ^b   Zlobec, Inti ^a   Inderbitzin, Daniel ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Spital Bern Tiefenau   (Switzerland)

^d Hospital Centre of Biel   (Switzerland)

Author keywords

Colorectal cancer; Immune infiltration; Nodal metastasis; Pre operative biopsies; Pre operative risk stratification; Prognostic factor

Indexed keywords

CD45RO ANTIGEN; CD8 ANTIGEN; CD45 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COLON BIOPSY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; RECTUM BIOPSY; REPRODUCIBILITY; SURVIVAL PREDICTION; SURVIVAL TIME; T LYMPHOCYTE; TUMOR INVASION; BIOPSY; COLORECTAL TUMOR; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; ANTIGENS, CD8; BIOPSY; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 84899529933     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-81     Document Type: Article

References (31)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Lugli A, Karamitopoulou E, Panayiotides I, Karakitsos P, Rallis G, Peros G, Iezzi G, Spagnoli G, Bihl M, Terracciano L, Zlobec I. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Canc 2009, 101:1382-1392.
3. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Canc Res 2007, 67:1883-1886.
4. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Canc 2013, 13:97-110.
5. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007, 50:151-162. 10.1111/j.1365-2559.2006.02551.x, 17204028.
6. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993, 36:627-635. 10.1007/BF02238588, 8348847.
7. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009, 33:134-141. 10.1097/PAS.0b013e318184cd55, 18971777.
8. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004, 127:385-394. 10.1053/j.gastro.2004.04.022, 15300569.
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
10. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1. 10.1186/1479-5876-10-1, 3269368, 22214470.
11. Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 2011, 59:482-495. 10.1111/j.1365-2559.2011.03975.x, 22034888.
12. Vayrynen JP, Tuomisto A, Klintrup K, Makela J, Karttunen TJ, Makinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Canc 2013, 109:1839-1847.
13. Giger OT, Comtesse SC, Lugli A, Zlobec I, Kurrer MO. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod Pathol 2012, 25:1048-1053. 10.1038/modpathol.2012.56, 22481282.
14. Rogers AC, Gibbons D, Hanly AM, Hyland JM, O'Connell PR, Winter DC, Sheahan K. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol 2013, 27:156-62.
15. Lugli A, Vlajnic T, Giger O, Karamitopoulou E, Patsouris ES, Peros G, Terracciano LM, Zlobec I. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol 2011, 42:1833-1840. 10.1016/j.humpath.2011.02.010, 21664647.
16. Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol 2011, 6:49. 10.1186/1748-717X-6-49, 3120676, 21575175.
17. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012, 10:51. 10.1186/1741-7015-10-51, 3362748, 22642691.
18. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998, 316:1236-1238. 10.1136/bmj.316.7139.1236, 1112991, 9553006.
19. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Canc 2012, 12:298-306.
20. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820. 10.1016/S0140-6736(09)60484-0, 2668947, 19269519.
21. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27:5124-5130. 10.1200/JCO.2009.22.0467, 2773471, 19770376.
22. Foxtrot Collaborative G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012, 13:1152-1160. 10.1016/S1470-2045(12)70348-0, 3488188, 23017669.
23. Quirke P, Risio M, Lambert R, von Karsa L, Vieth M. Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch 2011, 458:1-19. 10.1007/s00428-010-0977-6, 3016207, 21061133.
24. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. 10.1016/S0140-6736(07)61866-2, 18083404.
25. Dewhurst C, Rosen MP, Blake MA, Baker ME, Cash BD, Fidler JL, Greene FL, Hindman NM, Jones B, Katz DS, Lalani T, Miller FH, Small WC, Sudakoff GS, Tulchinsky M, Yaghmai V, Yee J. ACR appropriateness criteria pretreatment staging of colorectal cancer. J Am Coll Radiol 2012, 9:775-781. 10.1016/j.jacr.2012.07.025, 23122343.
26. Thoeni RF. Colorectal cancer. Radiologic staging. Radiol Clin North Am 1997, 35:457-485.
27. Wong SL. Lymph node counts and survival rates after resection for colon and rectal cancer. Gastrointest Canc Res 2009, 3:S33-S35.
28. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010, 28:272-278. 10.1200/JCO.2009.24.1448, 19949013.
29. West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol 2012, 30:1763-1769. 10.1200/JCO.2011.38.3992, 22473170.
30. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L, EORTC Radiation Oncology Group Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014, 15:184-190. 10.1016/S1470-2045(13)70599-0, 24440473, EORTC Radiation Oncology Group.
31. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012, 10:205. 10.1186/1479-5876-10-205, 3554496, 23034130.